Relationship Between MR Spectroscopy-Detected Glutamatergic Neurometabolites and Changes in Social Behaviors in a Pilot Open-Label Trial of Memantine for Adults With Autism Spectrum Disorder

Neetu Nair1,2, John Patrick Hegarty II3, Carmen Mihaela Cirstea4, Meng Gu3, Carrina Brooke Appling1 and David Quentin Beversdorf1,5*

1 Interdisciplinary Neuroscience Program, University of Missouri, Columbia, MO, United States, 2 Department of Psychiatry, University of Missouri, Columbia, MO, United States, 3 Department of Psychiatry, School of Medicine, Stanford University, Palo Alto, CA, United States, 4 Department of Physical Medicine and Rehabilitation, University of Missouri, Columbia, MO, United States, 5 William and Nancy Thompson Endowed Chair in Radiology, Departments of Radiology, Neurology and Psychological Sciences, University of Missouri, Columbia, MO, United States

**Background:** The neurobiology underlying ASD is largely unknown but altered neural excitability/inhibitory ratios have been reported. Memantine is an N-methyl-D-aspartate (NMDA) glutamatergic antagonist studied for the treatment of core ASD symptoms, with mixed results. We examined whether glutamatergic levels were associated with and predicted response to memantine in an exploratory pilot study.

**Methods:** Ten adult participants with ASD underwent proton magnetic resonance spectroscopy (1H-MRS) imaging at baseline and behavioral assessments before and after 12-weeks of open-label memantine. Post-treatment scores on Clinical Global Impressions–Improvement (CGI-I) for social interaction were the primary outcome measure, and scores on the Social Responsiveness Scale (SRS) were included as a secondary outcome. LCModel was used to quantify the concentrations of Point RESolved Spectroscopy-detected glutamate+glutamine (Glx) (and other neurometabolites, i.e., N-acetylaspartate, NAA; creatine+phosphocreatine, Cr+PCr, and myo-inositol, Ins), within the left dorsolateral prefrontal cortex (LDLPFC) and right (R) posterolateral cerebellum. SPM was used to perform brain tissue segmentation within the spectroscopic voxels. CGI-I scores post-treatment were used to classify the participants into two groups, responders (scores 1–3; n = 5) and non-responders (scores 4–7, or withdrew due to increase behaviors; n = 5). Independent samples t-tests, partial correlations and linear hierarchical regression models (SPSS) were used to determine between-group differences in neurometabolite concentrations and associations between neurometabolites and behavioral scores.
INTRODUCTION

Autism spectrum disorder (ASD) is a behaviorally defined, complex neurodevelopmental disorder characterized by early childhood onset of marked difficulties with social interaction and communication and the presentation of restrictive, repetitive patterns of behaviors and interests (1). Its phenotypic heterogeneity makes studying and treating ASD a challenging task (2). Currently, only two FDA approved drugs, risperidone and aripiprazole, are available to treat ASD and they are primarily used to manage severe irritability and aggression associated with ASD (3). Neither have shown conclusive benefit for the core features affecting social and communication skills in ASD and our understanding of the underlying neurobiology is only beginning to emerge. Some research indicates that a disrupted balance between excitation (glutamatergic) and inhibition (gamma amino-butric acid, GABAergic) may be a primary underlying mechanism of the ASD phenotype in some individuals (4, 5). Further, postmortem studies of the ASD brain indicate potential alterations in these components of the excitation-inhibition balance in individuals with ASD (4, 6–8). For instance, a number of postmortem studies have indicated deficits in expression of glutamatergic markers, and altered minicolumnary morphometry specific to the dorsolateral prefrontal cortex of individuals with autism (9). Similarly, postmortem studies have also identified the cerebellum as a region where glutamate and GABAergic abnormalities are consistently identified in individuals with autism (6, 9). In fact, animal studies provide preliminary evidence that GABAergic abnormalities in the cerebellum are directly related to glutamate transmission and release in the prefrontal cortex in autism models indicating a possible interplay between these two important regions in the neuropathology of autism tied to the excitation-inhibition imbalance hypothesis (10).

Results: Responders and non-responders did not significantly differ in Glx levels in any region of interest, but differed in NAA levels in LDLPFC (higher in responders vs. non-responders). Although changes in CGI-I social scores were not correlated with Glx in any region of interest, the linear hierarchical regression did reveal that Glx and Ins levels in LDLPFC were predictors of post-treatment CGI-I social scores. Changes in SRS scores were correlated with baseline Cr-+Pcr levels in the LDLPFC.

Discussion: Our pilot data suggest that baseline Glx, a marker of glutamatergic neurotransmission, did not directly predict response to memantine for social outcomes in adults with ASD. However, interactions between Glx and the neurometabolite associated with glial integrity (Ins) may help predict treatment response. Further, those with highest baseline NAA, a putative neuronal marker, and Cr-+Pcr, a brain energy metabolism marker, were the best responders. These preliminary results may explain some of the mixed results reported in previous memantine trials in ASD. Future studies will need to examine these results in a larger sample.

Keywords: autism, glutamate, magnetic resonance spectroscopy - MRS, social outcomes, memantine
communication deficits associated with ASD and the negative larger clinical trial could be clarified with better understanding of aspects of the biological heterogeneity of the disorder (18–21). In such a scenario, a biomarker to predict each individual patients’ treatment response would be invaluable for increasing treatment efficacy and decreasing trial and error.

The current pilot, clinical follow-on study used $^1$H MRS to examine whether Glx was associated with and could be used to predict treatment response to memantine in an open-label trial in adults with ASD. Since there is robust evidence supporting the role for the dorsolateral prefrontal cortex (DLPFC), the cerebellum, and their interconnection in the excitation-inhibition balance neuropathology of autism as described previously (6, 9), these two regions were selected as the regions of interest (ROI) for the current study. Specifically, our previous work had shown that the ratio between excitation (Glx) and inhibition (GABA) in the right (R) cerebellar hemisphere as well as connectivity between the left (L) DLPFC and the R cerebellum were associated with measures of social communication, (32) suggesting that these areas are reasonable target regions of interest to examine whether MRS markers of glutamatergic neurotransmission might predict response on social communication to glutameric antagonists. Additionally, abnormalities in the posterolateral cerebellar hemispheres appear to be associated with language and social communication, (37, 38) and project to the contralateral DLPFC (39, 40), and both regions are implicated in ASD pathology (41). We hypothesized that Glx levels in the LDLPFC and the R cerebellum will be predictive of changes in scores on social assessments after 12 weeks of treatment with memantine in a sample of 10 adult participants with ASD. Specifically, we expected that those with the highest Glx in these regions of interest would be the best responders on the social domain for CGI-I. In addition to the primary hypotheses concerning Glx, we examined other neurometabolites assessing neuronal health, viability, and quantity - N-acetylaspartate (NAA) (34), glial integrity (higher levels reflecting astroglial activation, gliosis, and inflammation) - myo-inositol (Ins) (35), and brain energy metabolism (creatine is well-established for its role in energy metabolism, and phosphocreatine is a potent antioxidant) - creatine and phosphocreatine (Cr+PCr) (36), to explore how they might be involved in treatment response and whether models that incorporate multiple neurometabolites may account for more variation in treatment response (42).

METHODS

Participants

Adolescent and adult patients with a confirmed diagnosis of ASD and who were willing to try memantine as an off-label clinical follow-on treatment were recruited through clinics at the Thompson Center for Autism and Neurodevelopmental Disorders, University of Missouri, Columbia, Missouri. General inclusion criteria were: (1) Age ≥ 16 years, (2) ASD diagnosis as per DSM V determined by clinician interview and confirmed with an Autism Diagnostic Interview-Revised (ADI-R) or Autism Diagnostic Observation Schedule (ADOS), and (3) Score <4 on the Clinical Global Impressions – Severity (CGI-S) scale indicating mild to moderate illness. The mild to moderate illness group was selected to ensure patient comfort and safety while taking the exploratory nature of the study into consideration. Exclusion criteria were: (1) Contraindications to MRI (Magnetic Resonance Imaging) (e.g., metallic implants, pacemakers, claustrophobia, pregnancy, lactation), (2) memantine intolerance or known hypersensitivity to memantine hydrochloride or to any components used in the formulation, and (3) medications that might interact with memantine. All procedures were approved by the University of Missouri Institutional Review Board and all participants (and legal guardians, for participants <18 years of age) provided written consent/assent, as applicable.

Measures

At baseline, participants were assessed on the following social and behavioral measures:

The Clinical Global Impressions – Severity (CGI-S) is a clinician rated scale (range one to seven, with one being no symptoms and seven being the most severe symptoms possible) to assess severity of symptoms, such as, social interaction, sensory sensitivities, restricted interests, verbal and non-verbal communication, etc. and is commonly used in ASD research (19, 21, 22). The CGI-S for social behavior was the focus in this study.

The Social Responsiveness Scale (SRS) is a well-validated 65 item questionnaire that specifically evaluates social deficits associated with ASD. Several studies in ASD have used SRS to track social outcomes in response to pharmacological interventions (21–29).

Imaging

Following baseline clinical assessments, subjects underwent an MRI scan, including structural MRI and $^1$H-MRS on a Siemens 3-Tesla TIM Trio MRI scanner located in the Brain Imaging Center at the University of Missouri. Participants were asked not to consume any forms of caffeine or alcohol 8 h before the scanning to eliminate effects from caffeine/alcohol on neurometabolites. High-resolution T1-weighted structural images were acquired using the three-dimensional multiplanar rapidly acquired gradient echo (MP-RAGE) pulse sequence: repetition time (TR), 2,500 ms; echo time (TE), 438 ms; flip angle, 8°, 256 × 256 voxel matrix; field of view (FOV), 256 mm; 176 axial slices; thickness, 1 mm. These images were used to quantify the brain tissue composition within the spectroscopic voxel and exclude any pathology. Based on anatomical landmarks, single voxel spectroscopy (SVS, 2 × 2 × 2 cm$^3$) with Point RESolved Spectroscopy (PRESS, TE = 80 ms, TR = 2,000 ms, 128 averages, flip angle=90°, water suppression bandwidth = 50 Hz, delta frequency = −2.3 ppm, bandwidth = 1,200 Hz) was prescribed to the right posterolateral hemisphere of the L cerebellum targeting crus I/II and the LDLPFC based on frontal gyral markers (Figure 1), brain regions previously identified as revealing changes in Glx/GABA and connectivity associated with performance on social communication (32). The same trained research personnel (NN) positioned the voxels on all the participants during the scanning sessions. Levels of Glx and other
metabolites (NAA, Ins, and Cr+PCr) were examined. To avoid lipid artifact from the skull, six outer voxel suppression saturation bands were applied around the SVS. Automated, followed by manual, shimming was performed to achieve an optimal full width at half maximum of <20 Hz of the water signal from the entire excitation volume. Internal reference water signal was also acquired by using non-water suppressed MRS imaging to calculate absolute concentrations of neurometabolites of interest.

**Memantine Administration**

Following the baseline imaging and behavioral assessment, participants were administered memantine, starting at 5 mg/day doses, and titrated up over 28 days to 20 mg/day based on response and tolerability, for a period of 12 weeks.

**Follow-Up Assessments**

Upon completion of the 12 weeks of memantine, the participants repeated clinical assessments using the CGI-S for social interaction and SRS. The CGI-I for social interaction (ratings from 1 to 7, with 4 being no change, and decreasing scores representing minimal (3), marked (2) and dramatic (1) improvement, and increasing scores similarly representing worsening) (19, 21, 22) was also assessed at this time point and the social interaction subscale of the CGI-I served as the primary outcome measure.

**Analyses**

Absolute concentrations of each metabolite- Glx, NAA, Ins, and Cr+PCr – measured in our regions of interest (ROI): LDLPFC and R cerebellum were quantified using Linear Combination of Model Spectra (LCModel) software [V6.3 (30)] with a standard PRESS basis set and water as internal concentration reference (31). The metabolites quantified in this manner serve as an estimate of their concentrations within the examined ROI (30, 31). Each metabolite of interest was expressed in institutional units (IU; ~ millimoles per kilogram wet weight) for each ROI. Gray matter volume within spectroscopy voxel was quantified using SPM (Mathworks Inc.) and controlled for during the statistical analysis. Processing of spectroscopic data is described in detail in our previous work (32).

For this pilot study, we summarized variables (primary: Glx; secondary: NAA, Ins, Cr+PCr) and outcomes (primary: scores on CGI-I for social interaction; secondary: SRS) measures by mean and standard deviation. To address our main hypothesis, responders and nonresponders were compared for Glx (and other neurometabolites) concentrations in each ROI using independent samples t-test. Pearson correlation analysis was also used to examine the relationships between Glx in each ROI and (1) scores on the social interaction subscale of the CGI-I social post-treatment and (2) changes in scores on the SRS baseline vs. post-treatment. Stepwise linear hierarchical regression models were used to examine whether baseline concentrations of neurometabolites (Glx, NAA, Ins, and Cr+PCr) in the LDLPFC and the R cerebellum predicted changes in scores on outcome measures using SPSS (IBM Corp, v26).

**RESULTS**

Ten participants (mean ± SD age = 24 ± 4 years, range 17–32 years old, one female, all Caucasian) were recruited to be a part of the study through the Thompson Center for Autism and Neurodevelopmental Disorders, University of Missouri, Columbia, Missouri. CGI-I scores on the social interaction subscale post 12 weeks of treatment with memantine were used to classify the participants into responders (scores 1–3, n = 5) and non-responders (scores 4–7, n = 3) (Figure 2).

Two subjects dropped out of the study at week 2 on memantine due to worsening behavioral symptoms, and were included in the non-responders group, as a result, for a total of n = 5 non-responders. No other side effects were reported.

All neurometabolites included in the analyses were within the limits required for spectra to be of acceptable quality: %SD <25 (%SD or Cramer Rao lower bounds, representing the threshold of the error associated with model fitting) and signal to noise >10. Due to head motion-related artifacts data from one participant had to be dropped from further analysis. Three other participants had high lipid contamination in the spectra acquired from the LDLPFC, suggesting tissue other than brain was included, and were not included in the corresponding models.

Overall, there were n = 9 participants with pre- and n = 7 participants with post-trial outcome data, of which n = 6 had high quality MRS data from the LDLPFC and n = 9 for the R cerebellum.

**Comparison of Responders and Non-responders**

When responders and non-responders were compared, with the two participants dropping out due to worsening symptoms categorized as non-responders, no significant differences were observed for either of the two defined ROIs for Glx (LDLPFC: responders 7.00 ± 0.87 IU, non-responders 5.11 ± 1.47 IU, t = −2.08, p = 0.10 (see Figure 3A); R cerebellum: responders: 7.95 ± 2.21 IU, non-responders: 6.86 ± 2.86 IU, t = −0.60, p = 0.57). However, the number of participants with high quality data in the non-respondor group was very limited for the LDLPFC, but if the p-value is to be believed, a larger sample size may reach statistical significance.

Our series of analysis of the secondary neurometabolites showed significantly higher levels of NAA in the LDLPFC in responders compared to the non-responders (9.78 ± 0.71 IU vs. 6.61 ± 1.65 IU, t = −3.56, p = 0.024) (see Figure 3B), again with a very limited number of non-responders with high quality data in the LDLPFC. A similar pattern, increased levels in responders vs. non-responders, was also observed for Cr+PCr levels in the R cerebellum; however, this difference did not reach statistical significance (responders: 12.34 ± 1.01 IU, non-responders 10.30 ± 1.35 IU, t = −2.13; p = 0.10).

**Correlations**

Partial correlations controlling for age and gray matter volume fraction within ROI revealed that CGI-I scores on the social interaction subscale posttreatment were not directly correlated with Glx (LDLPFC: r = −0.76, p = 0.24...
Hierarchical Regression Models

Linear hierarchical regression models revealed that a final model with Glx \( (B = -1.07, p = 0.02) \) and Ins \( (B = 0.58, p = 0.04) \) in the LDLPFC at baseline significantly predicted scores on the social interaction CGI-I posttreatment \( (R^2 \text{ adjusted} = 0.86, F = 9.188, p = 0.05) \).

DISCUSSION

This pilot study examined whether \(^1\)H-MRS-detected Glx (and other neurometabolites) in two targeted brain regions was associated with or could predict treatment response to a moderate affinity NMDA receptor antagonist, memantine, in adults and adolescents with ASD. Five participants did respond (scores of 1–3 on the CGI-I for social interaction) while five did not respond (scores of 4–7, or stopped due to increased behaviors) to memantine. Our preliminary data did not reveal a relationship between baseline Glx levels in either ROI and response to memantine. However, Glx along with Ins within the LDLPFC was found to predict the post-treatment scores on the social interaction subscale of the CGI-I. Specifically, it appears that higher levels of Glx and lower levels of Ins in the LDLPFC were predictive of lower scores on the CGI-I (or greater improvement) following treatment with memantine.

Additionally, higher levels of Cr+PCr in the LDLPFC at baseline were associated with decreases in SRS total score post treatment. Higher NAA levels were also found in the LDLPFC in responders than in non-responders. Since creatine levels reflect cellular energy metabolism and NAA levels are connected to energy metabolism in neuronal mitochondria, these results may indicate that the effectiveness of memantine treatment...
was dependent on the level of mitochondrial dysfunction, a phenomenon commonly noted in ASD pathology (33), in the LDLPFC. However, these results will need confirmation in larger samples. Additionally, larger samples will allow the possibility of understanding how factors such as head circumference and intellectual functioning might relate to these findings.

These preliminary results are an initial effort to understand the mixed results reported in previous studies using memantine in ASD. It is possible that there exist different subsets of autism that respond differently to this treatment. Our hypothesis was that glutamatergic levels would predict response. However, the preliminary evidence suggests that there may be a more complex relationship, where increased glutamatergic levels, in the additional setting of altered glial and cellular energy metabolism markers, in the LDLPFC may show more improvements with memantine. Additionally, when responders were compared to
have suggested that memantine might better target cognitive outcomes in ASD rather than social (prognosis and individualizing treatments in ASD. Recent studies for clinical care including improving accuracy of individual selection of patients capable of participating in the imaging session without sedation likely also introduces a bias in the findings, further impacting generalizability. Future studies should, therefore, be performed with larger samples. Additionally, while our study specifically targeted Glx since the drug memantine targets glutamate receptors, it would be critical for future work to gain a better understanding of the more complete role of the balance in excitation/inhibition in predicting the effects of memantine or related agents, including targeting GABA. Expanding the regions of interest to include other regions within the networks involved in social communication would also be critical in future studies, in addition to incorporating newer automated techniques for ROI optimization to improve outcomes.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by University of Missouri. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

DB, JH, and NN designed the project. NN implemented the work with DB. CC oversaw the MRS aspects throughout. MG also helped guide the MRS analysis. CA helped to retrieve and prepare the data from the database in preparation for the analysis by MG. All authors contributed to the article and approved the submitted version.

FUNDING

Research was supported by the University of Missouri Research Board Grant (PI: DB). ClinicalTrials.gov number: NCT02811627.

REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th ed. Washington, DC: American Psychiatric Association (2013). doi: 10.1176/appi.books.9780890425596
2. Beversdorf DQ, Consortium MAS. Phenotyping, etiological factors, and biomarkers: toward precision medicine in autism spectrum disorders. J Dev Behav Pediatr. (2016) 37:659–73. doi: 10.1097/DBP.0000000000000351
3. LeClerc S, Easley D. Pharmacological therapies for autism spectrum disorder: a review. P T. (2015) 40:389–97.
4. Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat Rec. (2011) 294:1646–52. doi: 10.1002/ar.21252
5. Siegel-Ramsay JE, Romanisk L, Whalley HC, Roberts N, Branigan H, Stanfield AC, et al. Glutamate and functional connectivity - support for the excitatory-inhibitory imbalance hypothesis in autism spectrum disorders. Psych Res - Neuroimag. (2021) 313:111302. doi: 10.1016/j.pscychresns.2021.111302
6. Purcell A, Leon OH, Zimmerman a W, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. (2001) 57:1618. doi: 10.1212/00005853-200107110-00061
7. Fatemi SH, Folsom TD, Reutiman T, Thurais P, Expression of GABAB receptors is altered in brains of subjects with autism. Cerebellum. (2009) 8:64–9. doi: 10.1007/s12311-008-0075-3
8. Fatemi SH, Reutiman T, Folsom TD, Thurais P, GABA. Receptor downregulation in brains of subjects with autism. J Autism Dev Disord. (2009) 39:223–30. doi: 10.1007/s10803-008-0646-7
9. Feit T, Hillary RF, Price DJ, Lawrie SM. The neuropathology of autism: a systematic review of post-mortem studies of autism and related disorders. Neurosci Biobehav Rev. (2021) 129:35–62. doi: 10.1016/j.neubiorev.2021.07.014
10. McKimm E, Corkill B, Goldowitz D, et al. Glutamate dysfunction associated with developmental cerebellar damage: Relevance to autism spectrum disorders. *Cerebellum.* (2014) 13:346–53. doi: 10.1007/s12311-013-0541-4

11. Baruth JM, Wall CA, Patterson MC, Port JD. Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review. *Autism Res.* (2013) 6:119–33. doi: 10.1002/aur.1273

12. Fujiwara T, Moriyama S, Hashimoto T, Harada M, Kagami S. Function of the frontal lobe in autistic individuals: a proton magnetic resonance spectroscopic study. *J Med Invest.* (2010) 57:35–44. Available online at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&Bst_uids=20299741. doi: 10.2152/jmi.57.35

13. Margari L, De Giacomo A, Craig F, et al. Frontal lobe metabolic alterations in autism spectrum disorder: a 1H-magnetic resonance spectroscopy study. *Neuropsychiatr Dis Treat.* (2018) 14:1871–6. doi: 10.2147/NDT.S165375

14. Ajram LA, Pereira AC, Durieux AMS, Velthius HE, Petrinovic MM, McAlonan GM. The contribution of [1H] magnetic resonance spectroscopy to the study of excitation-inhibition in autism. *Prog Neuro-Psychopharmacol Biol Psych.* (2019) 89:236–44. doi: 10.1016/j.pnpbp.2018.09.010

15. Otsuka H, Harada M, Mori K, Hisaoka S, Nishitani H. Brain metabolites of the hippocampus-amygdaIa region and cerebellum in autism: An 1H-MR spectroscopy study. *Neuropsychologia.* (1999) 37:517–9. doi: 10.1016/S0028-3932(98)00135-X

16. Rojas DC, Singel D, Steinmetz S, Hepburn S, Brown MS. Decreased left perisylvian GABA concentration in children with autism and unaffected siblings. *Neuroimage.* (2014) 86:28–34. doi: 10.1016/j.neuroimage.2013.01.045

17. Schulz JB, Rainer M, Klünemann HH, Kurz A, Wolf S, Sternberg K, et al. Efficacy of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer’s disease: results of a 16-week open-label trial. *J Alzheimer’s Dis.* Available online at: http://www.jo.sagepub.com/download/journal-of-alzheimers-disease/jad101929f1/d=journal-of-alzheimers-disease%2Fjad101929 (accessed November 5, 2015).

18. Soorya LV, Fogel L, Ocampo E, et al. Neurocognitive outcomes from memantine: a pilot, double-blind, placebo-controlled trial in children with autism spectrum disorder. *J Child Adolesc Psychopharmacol.* (2021) 31:475–84. doi: 10.1089/jcp.2021.0010

19. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ, et al. Retrospective study of memantine in children and adolescents with pervasive developmental disorders. *Psychopharmacology.* (2007) 191:141–7. doi: 10.1007/s00213-006-0518-9

20. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorder: an observation of initial clinical response and maintenance tolerability. *J Child Neurol.* (2007) 22:574–9. doi: 10.1177/0883073807302611

21. Ghaleiba A, Asadabadi M, Mohammadi M-R, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. *Int J Neuropsychopharmacol.* (2013) 16:783–9. doi: 10.1017/S1461145712000880

22. Frye RE. Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. *Drug Healthc Patient Saf.* (2014) 6:69–76. doi: 10.2147/DHPS.S39595

23. Rossignol D, Frye RE. The use of medications approved for Alzheimer’s disease in autism spectrum disorders: a systematic review. *Front Pediatr, Child Neuropsych.* (2014) 2:1–8. doi: 10.3389/fped.2014.00087

24. Brown MS, Singel D, Hepburn S, Rojas DC. Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a 1H-MRS study. *Autism Res.* (2013) 6:1–10. doi: 10.1002/aur.1260

25. Rojas DC, Singel D, Steinmetz S, Hepburn S, Brown MS. Decreased left perisylvian GABA concentration in children with autism and unaffected siblings. *Neuroimage.* (2014) 86:28–34. doi: 10.1016/j.neuroimage.2013.01.045

26. Tebart van Elst L, Maier S, Fangmeier T, Endres D, Mueller GT, Leggio MG. The cerebellar cognitive profile. *Brain.* (2011) 134:3672–86. doi: 10.1093/brain/awr305

27. D’Angelo E, Casali S. Seeking a unified framework for cerebellar function and dysfunction: from circuit operations to cognition. *Front Neural Circ.* (2012) 6:116. doi: 10.3389/fncir.2012.00116

28. Ohyama T, Nores WL, Murphy M, Mauk MD. What the cerebellum computes. *Trends Neurosci.* (2003) 26:222–7. doi: 10.1016/S0166-2236(03)00547-3

29. Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. *Trends Neurosci.* (2008) 31:137–45. doi: 10.1016/j.tins.2007.12.005

30. Provencher SW. Automatic quantitation of localized in vivo 1H spectrum with L.Cmodel. *NMR Biomed.* (2014) 27:164–6. doi: 10.1002/nbm.3911

31. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. *Prog Brain Res.* (2007) 81:89–131. doi: 10.1016/S0079-6194(06)50002-9

Conflict of Interest: DB has received support for consulting with Impel Pharma, Stalicla Biosciences, Quadrant Biosciences, Scioto Pharma, and YAMO Pharma in the past year unrelated to this work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Nair, Hegarty, Cirstea, Gu, Appling and Beverdorsh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Frontiers in Psychiatry | www.frontiersin.org 8 July 2022 | Volume 13 | Article 898006